Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Yongfeng Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5820-6429; OpenAlex author ID A5051303998. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 2 papers · 2024: 2 papers

Papers 9

  1. tiRNA-Val-CAC-2 interacts with FUBP1 to promote pancreatic cancer metastasis by activating c‑MYC transcription. Co-author DOI 10.1038/s41388-024-02991-9↗
  2. Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. First author DOI 10.7717/peerj.18018↗
  3. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer. Co-author DOI 10.1002/cam4.5774↗
  4. The PD-L1 Expression and Tumor-Infiltrating Immune Cells Predict an Unfavorable Prognosis in Pancreatic Ductal Adenocarcinoma and Adenosquamous Carcinoma. Co-author DOI 10.3390/jcm12041398↗
  5. Serum Nardilysin as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm11113101↗
  6. Pancreatic Adenosquamous Carcinoma: A Rare Pathological Subtype of Pancreatic Cancer. Co-author DOI 10.3390/jcm11247401↗
  7. Krüppel-like Factor 6 Suppresses the Progression of Pancreatic Cancer by Upregulating Activating Transcription Factor 3. Co-author DOI 10.3390/jcm12010200↗
  8. Identification of Novel Molecular Therapeutic Targets and Their Potential Prognostic Biomarkers Among Kinesin Superfamily of Proteins in Pancreatic Ductal Aden… Co-author DOI 10.3389/fonc.2021.708900↗
  9. RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy. Co-author DOI 10.4161/cbt.13.4.18692↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qunli Xiong · 8 shared papers, 2021–2024 · strength 1.49
  2. Qing Zhu · 7 shared papers, 2021–2024 · strength 1.27
  3. Zhiwei Zhang · 6 shared papers, 2022–2024 · strength 1.19
  4. Jinlu Liu · 3 shared papers, 2022–2024 · strength 0.49
  5. Zhu Zeng · 2 shared papers, 2023–2024 · strength 0.36
  6. Ying Zheng · 2 shared papers, 2022–2024 · strength 0.34
  7. Ningna Weng · 2 shared papers, 2021–2022 · strength 0.27
  8. Ying Cao Xu · 1 shared paper, 2024 · strength 0.26
  9. Qing Zhu · 1 shared paper, 2022 · strength 0.22
  10. Congya Zhou · 1 shared paper, 2023 · strength 0.18
  11. Yang Yang · 1 shared paper, 2023 · strength 0.18
  12. Yang Yang · 1 shared paper, 2021 · strength 0.12
  13. Quanxing Ni · 1 shared paper, 2012 · strength 0.03
  14. Jin Xu · 1 shared paper, 2012 · strength 0.03
  15. Wenyan Xu · 1 shared paper, 2012 · strength 0.03
  16. Xianjun Yu · 1 shared paper, 2012 · strength 0.03
  17. Wantong Yao · 1 shared paper, 2012 · strength 0.03
  18. Shunrong Ji · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.